- Home
- VRE vs OCS Comparison
VRE vs OCS Comparison
Compare VRE & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRE | OCS |
|---|---|---|
| Founded | 1949 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | VRE | OCS |
|---|---|---|
| Price | $16.84 | $29.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $18.67 | ★ $39.57 |
| AVG Volume (30 Days) | ★ 713.2K | 305.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ 79.51 | N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $271,074,000.00 | N/A |
| Revenue This Year | $4.77 | $14.53 |
| Revenue Next Year | N/A | $691.13 |
| P/E Ratio | $20.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.69 | $14.00 |
| 52 Week High | $17.12 | $29.50 |
Technical Indicators
Market Signals| Indicator | VRE | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 69.31 | 64.14 |
| Support Level | $16.60 | $28.05 |
| Resistance Level | $17.05 | $29.09 |
| Average True Range (ATR) | 0.44 | 1.01 |
| MACD | 0.08 | -0.22 |
| Stochastic Oscillator | 89.11 | 76.12 |
Price Performance
Historical ComparisonAbout VRE Veris Residential Inc.
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.